Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Airbus Spain Workers Approve Deal to End Months of Strikes 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Add as a preferred source on Google
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
